Cutaneous Hemangiomas and Signal Transduction
Cutaneous Hemangiomas and Signal Transduction
批准号:
7677372
负责人:
JACK L ARBISER
金额:
$27.28万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-09-01 至 2013-06-30
关键词:
1 year oldAccountingAdverse effectsAffectAngiogenesis InhibitorsBehaviorBenignBiologyBlood VesselsCarbazolesCell LineCell ProliferationCellsCessation of lifeChildChildhoodClinicalCommon NeoplasmCutaneousDataDeformityDevelopmentDiagnosisDiseaseDoseEffector CellEndothelial CellsEventFundingGenesGrowthGrowth FactorHeart failureHemangiomaHemangiosarcomaHumanInfantInfectionInflammationInflammatoryInterferon-alphaInterferonsKaposi SarcomaKnock-outLeadLesionLigandsLimb structureLymphaticMalignant - descriptorMediatingMedicalMedicineModelingMorbidity - disease rateMusNeoplasmsNeuropathyOperative Surgical ProceduresOutputOxygenPainParaffinPathogenesisPhysiologicalPlayPreventionProcessPublishingRegulator GenesRepressionRoleSignal PathwaySignal TransductionSignal Transduction PathwaySkinSteroidsStructureTechnologyTestingTimeVascular remodelingWT1 geneangiogenesiscarbazoleefficacy testingfunctional disabilityhonokiolin vivoinfancyinhibitor/antagonistinsightmalformationmigrationnotch proteinnovelnovel therapeutic interventionpreventpublic health relevancereceptorresponseskin disorderskin lesionsmall moleculetriphenylmethanetumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This application focuses on the mechanisms of pathogenesis of hemangiomas and associated angiogenesis. Hemangiomas are the most common cutaneous vascular lesions of childhood, and are present in 5 percent of infants at 1 year of age. These hemangiomas may grow to large sizes and may result in compression of vital structures or high output cardiac failure. Treatment of large hemangiomas requires lengthy treatment with steroids or alpha interferon, and surgery. These treatments are associated with a high level of morbidity, including growth retardation, infection, and irreversible neuropathy. A significant number of these hemangiomas do not respond to treatment, resulting in death. Vascular malformations represent another skin lesion of childhood with considerable morbidity. Initially, vascular malformations may resemble hemangiomas, but unlike hemangiomas, vascular malformations do not spontaneously regress. Instead, they tend to enlarge with time, causing pain, deformity, and limb overgrowth. Unlike hemangiomas, there are no medical treatments for vascular malformations. Studies performed during the last funding period have suggested that hemangiomas and vascular malformations can be distinguished by signaling pathways. We have found that model hemangioma cells require a combination of reactive oxygen and akt activation, while model vascular malformation cells use akt activation alone. In addition, we have found that the developmentally important gene Wilms tumor 1 (WT-1) is present in hemangiomas, but not in vascular malformations. We plan to investigate whether WT-1 is necessary for physiologic endothelial regression. Hypothesis: Differences in signal transduction can predict the behavior of endothelial neoplasms in vivo. Specific Aim 1. To determine the presence of Notch ligands and receptors in human vascular lesions and functional role of Notch ligands in murine bend3 hemangiomas. Specific Aim 2. To determine the downstream signaling events of nox4 and reactive oxygen in vascular lesions. Specific Aim 3. To determine the role of the Wilms tumor 1 gene in endothelial remodeling and formation of vascular malformations. The studies outlined in this application will contribute to our basic understanding of cutaneous angiogenesis. In addition, insights gained from the studies described in this application may lead to novel therapeutic approaches to cutaneous disease through signal transduction modulation. Indeed, discoveries made during the prior funding cycle include small molecule angiogenesis inhibitors such as honokiol, solenopsin, carbazole, and triphenylmethanes.
PUBLIC HEALTH RELEVANCE: Hemangiomas and vascular malformations are the most common vascular lesions of children, and cause a considerable deal of morbidity because of functional impairment of vital structures and deformity. The biology of these lesions is not fully understood, and the treatment of these lesions causes side effects due to medicines and extensive surgery. The studies in this application have the potential of developing new treatments for these disorders that do not have the side effects of current therapy and given that the same processes may be occurring in other disorders, such as skin inflammation and tumors, advances from these studies may lead to better treatments for skin inflammation and tumors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ceramide Analog Control of Cutaneous Inflammation
-
批准号:10368633
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2022
-
负责人:JACK L ARBISER
-
依托单位:
Palladium based nanoparticles for the treatment of advanced melanoma
-
批准号:9206894
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:JACK L ARBISER
-
依托单位:
Skin Manifestations of Tuberous Sclerosis
-
批准号:7674820
-
项目类别:
-
资助金额:$21.89万
-
财政年份:2005
-
负责人:JACK L ARBISER
-
依托单位:
Skin Manifestations of Tuberous Sclerosis
-
批准号:7483282
-
项目类别:
-
资助金额:$21.89万
-
财政年份:2005
-
负责人:JACK L ARBISER
-
依托单位:
Skin Manifestations of Tuberous Sclerosis
-
批准号:7035486
-
项目类别:
-
资助金额:$23.56万
-
财政年份:2005
-
负责人:JACK L ARBISER
-
依托单位:
Skin Manifestations of Tuberous Sclerosis
-
批准号:7278673
-
项目类别:
-
资助金额:$22.34万
-
财政年份:2005
-
负责人:JACK L ARBISER
-
依托单位:
Skin Manifestations of Tuberous Sclerosis
-
批准号:7126507
-
项目类别:
-
资助金额:$23.01万
-
财政年份:2005
-
负责人:JACK L ARBISER
-
依托单位:
Cutaneous Hemangiomas and Signal Transduction
-
批准号:6649140
-
项目类别:
-
资助金额:$25.27万
-
财政年份:2001
-
负责人:JACK L ARBISER
-
依托单位:
Cutaneous Hemangiomas and Signal Transduction
-
批准号:8856496
-
项目类别:
-
资助金额:$34.32万
-
财政年份:2001
-
负责人:JACK L ARBISER
-
依托单位:
Cutaneous Hemangiomas and Signal Transduction
-
批准号:8103817
-
项目类别:
-
资助金额:$25.93万
-
财政年份:2001
-
负责人:JACK L ARBISER
-
依托单位:
Cutaneous Hemangiomas and Signal Transduction
-
批准号:7526359
-
项目类别:
-
资助金额:$27.28万
-
财政年份:2001
-
负责人:JACK L ARBISER
-
依托单位:
Cutaneous Hemangiomas and Signal Transduction
-
批准号:7902102
-
项目类别:
-
资助金额:$27.01万
-
财政年份:2001
-
负责人:JACK L ARBISER
-
依托单位:
Cutaneous Hemangiomas and Signal Transduction
-
批准号:8289627
-
项目类别:
-
资助金额:$25.93万
-
财政年份:2001
-
负责人:JACK L ARBISER
-
依托单位:
Cutaneous Hemangiomas and Signal Transduction
-
批准号:6783467
-
项目类别:
-
资助金额:$25.27万
-
财政年份:2001
-
负责人:JACK L ARBISER
-
依托单位:
Cutaneous Hemangiomas and Signal Transduction
-
批准号:6912811
-
项目类别:
-
资助金额:$25.27万
-
财政年份:2001
-
负责人:JACK L ARBISER
-
依托单位:
Cutaneous Hemangiomas and Signal Transduction
-
批准号:6364997
-
项目类别:
-
资助金额:$25.27万
-
财政年份:2001
-
负责人:JACK L ARBISER
-
依托单位:
Cutaneous Hemangiomas and Signal Transduction
-
批准号:6512122
-
项目类别:
-
资助金额:$25.27万
-
财政年份:2001
-
负责人:JACK L ARBISER
-
依托单位:
Cutaneous Hemangiomas and Signal Transduction
-
批准号:9070292
-
项目类别:
-
资助金额:$34.32万
-
财政年份:2001
-
负责人:JACK L ARBISER
-
依托单位:
ROLE OF CORTICOTROPIN RELEASING HORMONE IN ANGIOGENESIS
-
批准号:6100605
-
项目类别:
-
资助金额:$6.87万
-
财政年份:1999
-
负责人:JACK L ARBISER
-
依托单位:
PATHOPHYSIOLOGY OF CUTANEOUS VASCULAR LESIONS
-
批准号:6532911
-
项目类别:
-
资助金额:$10.84万
-
财政年份:1998
-
负责人:JACK L ARBISER
-
依托单位:
海外基金